Home / Central Data Catalog / FRESH-PEF73495-EN
central

Morbidity-mortality of COVID-19 in patients with chronic rheumatic disorder treated with immunosuppressants

France
Reference ID
FRESH-PEF73495-en
Producer(s)
Jean-Guillaume;LETAROUILLY
Metadata
DDI/XML JSON
Study website Interactive tools
Created on
Feb 18, 2026
Last modified
Feb 18, 2026
Page views
39
  • Identification
  • Scope
  • Coverage
  • Producers and sponsors
  • Study authorization
  • Sampling
  • Survey instrument
  • Data collection
  • Data Access
  • Contacts

    • Identification

    Survey ID number

    FRESH-PEF73495-en
    Title

    Morbidity-mortality of COVID-19 in patients with chronic rheumatic disorder treated with immunosuppressants
    Abbreviation or Acronym

    CORhum
    Country
    Name Country code
    France fr
    Kind of Data

    ['Clinical data']
    Unit of Analysis

    Individuals

    Scope

    Topics
    Topic Vocabulary
    Internal medicine health theme
    Rheumatology health theme
    Lupus erythematosus cim-11
    Inflammatory arthropathies cim-11
    COVID-19 cim-11
    Keywords
    systemic lupus erythematosus spondyloarthritis chronic rheumatic disorder biological therapy rheumatoid arthritis immunosuppressants

    Coverage

    Geographic Coverage

    ['Hauts-de-France']
    Universe

    {"level_sex_clusion_I":[{"value":"Male","concept":{"vocab":"MeSH","vocabURI":"D008297"}},{"value":"Female","concept":{"vocab":"MeSH","vocabURI":"D005260"}}],"level_age_clusion_I":[{"value":"Young Adult (19 to 24 years)","concept":{"vocab":"MeSH","vocabURI":"D055815"}},{"value":"Adult (25 to 44 years)","concept":{"vocab":"MeSH","vocabURI":"D000328"}},{"value":"Middle Aged (45 to 64 years)","concept":{"vocab":"MeSH","vocabURI":"D008875"}},{"value":"Aged (65 to 79 years)","concept":{"vocab":"MeSH","vocabURI":"D000368"}}],"level_type_clusion_I":"Patients population","level_type_clusion_other":"","clusion_I":"Patients with RA on csDMARD +/- bDMARD or tsDMARD +/- corticosteroid therapy fulfilling 2010 ACR/EULAR classification criteria? Patients with SpA receiving bDMARD or tsDMARD +/- csDMARD +/- non-steroidal anti-inflammatory drugs fulfilling ASAS classification criteria? Patients with SLE receiving hydroxychloroquine +/- csDMARD +/- corticosteroid therapy +/- bDMARD fulfilling 2019 ACR/EULAR classification criteria","clusion_E":""}

    Producers and sponsors

    Primary investigators
    Name
    Jean-Guillaume;LETAROUILLY
    Producers
    Name Role
    CENTRE HOSPITALIER UNIVERSITAIRE DE LILLE (CHU) sponsor

    Study authorization

    Agency
    Agency name
    CNIL
    CPP
    Other

    Sampling

    Sample frame

    Unit Type

    ['']
    Sampling Procedure

    ['{"concept":{"vocabURI":"Other","vocab":"CESSDA"},"value":"Other"}']

    Survey instrument

    Methodology notes

    Observational Study

    Data collection

    Time Method

    One-time cross-sectional study
    Mode of data collection
    • {"concept":{"vocabURI":"Transcription","vocab":"CESSDA"},"value":"Converting or copying information into a structured record"}
    • {"concept":{"vocabURI":"Interview","vocab":"CESSDA"},"value":"Interview with the participant (including clinical)"}

    Data Access

    Availability Status

    {"value":"To be defined","extLink":[]}

    Contacts

    Contacts
    Name Email
    Jean-Guillaume;LETAROUILLY jeanguillaume.letarouilly@chu-lille.fr
    Back to Catalog